CSL -3.4%: Healthcare Selloff Needs Watching
CSL dropped -$11.73 to $334.85 (-3.38%) with no material company-specific news — the decline appears driven by global healthcare sector rotation (US Healthcare +0.66% diverged, showing this is ASX-specific). CSL's AUD-denominated earnings are partially hedged via USD revenue (plasma products exported globally), so AUD weakness typically supports, not pressures, the name. At $334.85, CSL is approaching the low end of its 12-month trading range. Motley Fool Australia flagged ASX 300 names with broker upgrades — CSL at these levels historically attracts super fund accumulation given its defensive-growth profile.
Read at Motley Fool Australia ↗